ArticleCureus2025
A Retrospective Study of Rabbit Anti-T Lymphocyte Globulin (rATLG) as a Second-Line Therapy in Transplant-Ineligible Severe Aplastic Anemia Patients.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere aplastic anemia (SAA) is a potentially fatal disorder of bone marrow failure with a high risk of life-threatening infections and bleeding. While matched sibling donor transplantation remains the preferred therapy, immunosuppressive treatment with horse anti-thymocyte globulin (hATG), cyclosporine, and eltrombopag is the standard first-line option for non-transplant candidates. However, a significant proportion of patients fail to respond, and access to allogeneic transplantation is severely restricted in resource-limited settings due to prohibitive costs and infrastructure constraints. In such scenarios, rabbit anti-T lymphocyte globulin (rATLG) emerges as an important second-line salvage therapy.
methodsThis hospital-based retrospective study included 10 patients with SAA or very severe aplastic anemia (VSAA), aged ≥13 years, treated at King George's Medical University, Lucknow, between 2020 and 2024. All patients had relapsed or refractory disease following hATG and were ineligible for transplantation. rATLG was administered at 3.5 mg/kg/day for five days alongside cyclosporine and eltrombopag. Responses were assessed at three, six, and 12 months, with survival analysed using Kaplan-Meier (KM) estimates (censoring applied for patients alive or lost to follow-up at the last contact).
resultsThe cohort had a median age of 23 years, with 70% (7/10 patients) classified as SAA and 30% (3/10 patients) as VSAA. Four had refractory disease, six had relapsed disease, and three harboured a PNH clone. At 12 months, 40% (4/10 patients) achieved partial response; no complete responses were observed. Overall survival (OS) at two years was 78% (95% CI: 40.3-94.9) by KM estimate. The most common adverse events were fever, pruritus, hepatic dysfunction, and infections.
conclusionAlthough modest in efficacy, rATLG offers a clinically meaningful salvage option in transplant-ineligible SAA patients, particularly in low-resource settings where curative transplantation is often inaccessible. Our findings underscore the role of rATLG as a bridge therapy, while highlighting the urgent need for wider access to definitive curative options in developing countries.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.